Review




Structured Review

GraphPad Software Inc survival calculation tool graphpad prism
Survival Calculation Tool Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/survival calculation tool graphpad prism/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
survival calculation tool graphpad prism - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

90
GraphPad Software Inc survival calculation tool graphpad prism
Survival Calculation Tool Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/survival calculation tool graphpad prism/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
survival calculation tool graphpad prism - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc statistical calculations graphpad prism 8
Statistical Calculations Graphpad Prism 8, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/statistical calculations graphpad prism 8/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
statistical calculations graphpad prism 8 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc area under the curve (auc) calculated by graphpad prism
Area Under The Curve (Auc) Calculated By Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/area under the curve (auc) calculated by graphpad prism/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
area under the curve (auc) calculated by graphpad prism - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc roc curve calculated using graphpad prism software
Roc Curve Calculated Using Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/roc curve calculated using graphpad prism software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
roc curve calculated using graphpad prism software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
Pearson’s Correlation Coefficient(R) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pearson’s correlation coefficient(r) calculated in graphpad prism/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc statistical significance calculated by graphpad prism 8.0
a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
Statistical Significance Calculated By Graphpad Prism 8.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/statistical significance calculated by graphpad prism 8.0/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
statistical significance calculated by graphpad prism 8.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc logic50 values calculated by graphpad prism 6 program
% cell viability and <t> LogIC50 </t> (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.
Logic50 Values Calculated By Graphpad Prism 6 Program, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/logic50 values calculated by graphpad prism 6 program/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
logic50 values calculated by graphpad prism 6 program - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc ic50 calculation software graphpad prism 8.0
% cell viability and <t> LogIC50 </t> (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.
Ic50 Calculation Software Graphpad Prism 8.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ic50 calculation software graphpad prism 8.0/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
ic50 calculation software graphpad prism 8.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc anova or t-students test calculations using graphpad prism v.9.4.1
% cell viability and <t> LogIC50 </t> (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.
Anova Or T Students Test Calculations Using Graphpad Prism V.9.4.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anova or t-students test calculations using graphpad prism v.9.4.1/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
anova or t-students test calculations using graphpad prism v.9.4.1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GraphPad Software Inc non-linear regression analysis with variable slope calculation in graphpad prism 8.0
% cell viability and <t> LogIC50 </t> (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.
Non Linear Regression Analysis With Variable Slope Calculation In Graphpad Prism 8.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non-linear regression analysis with variable slope calculation in graphpad prism 8.0/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
non-linear regression analysis with variable slope calculation in graphpad prism 8.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

doi: 10.1038/s41467-025-59588-3

Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

Techniques: Comparison, Clinical Proteomics, Two Tailed Test

% cell viability and  LogIC50  (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.

Journal: Journal of Biochemical and Molecular Toxicology

Article Title: The First Chalcone Derivatives of Valine‐Based Spiro‐Cyclotriphosphazenes: In Vitro Cytotoxic Properties, Molecular Docking and DNA Damage Mechanism Studies

doi: 10.1002/jbt.70233

Figure Lengend Snippet: % cell viability and LogIC50 (concentration causing 50% inhibition) values (µM) of the compounds in A2780, Caco‐2 cell lines (Bold: * p < 0.05 compared to control group, # p < 0.05 compared to solvent group) reference drug: TX: Tamoxifen, DX: Docetaxel.

Article Snippet: LogIC50 values were calculated by Graphpad Prism 6 program according to MTT results [ , ].

Techniques: Concentration Assay, Inhibition, Control, Solvent